filgotinib vs Zemprocitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: JAK1 · full Rheumatoid Arthritis pipeline

filgotinib · Jyseleca

Marketed by Gilead Sciences and partners

Phase 3 in Rheumatoid ArthritisSmall molecule (JAK1-selective inhibitor)
Reliable signal

NCT02873936 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 449 patients; the primary endpoint, ACR20 response at week 12 (a validated rheumatoid-arthritis disease-activity measure), was significantly higher with both filgotinib doses than placebo (66.0% and 57.5% vs 31.1%, both p<0.001).

Next expected readout: April 2029 · NCT06687551 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001) (met)

Result source: NCT02889796

Zemprocitinib

Developed by Lynk Pharmaceuticals and partners

Phase 3 in Rheumatoid Arthritissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfilgotinibZemprocitinib
ACR2076.6% vs 49.9%+26.7 vs placebo200 mg · wk 12 · n 475NCT02889796
51 other results
  • 69.8% vs 49.9% 100 mg · wk 12 · n 480 · Phase 3 · primary NCT02889796
  • 66% vs 31.1% 200 mg · wk 12 · n 147 · Phase 3 · primary NCT02873936
  • 57.5% vs 31.1% 100 mg · wk 12 · n 153 · Phase 3 · primary NCT02873936
  • 78.1% vs 71.4% 200 mg · wk 24 · n 210 · Phase 3 · primary NCT02886728
  • 81% vs 71.4% 200 mg · wk 24 · n 416 · Phase 3 · primary NCT02886728
  • 80.2% vs 71.4% 100 mg · wk 24 · n 207 · Phase 3 · primary NCT02886728
  • 82.9% vs 85.9% 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • 82.9% vs 86.9% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 78.1% vs 59.2% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 51.6% vs 31.8% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 37.3% vs 14.9% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 79.6% vs 85.9% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 79.2% vs 86.9% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 77.7% vs 59.2% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 45.6% vs 31.8% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 27.5% vs 14.9% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 69.4% vs 34.5% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 51.7% vs 25.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 54.9% vs 34.5% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 44.4% vs 25.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 74.8% vs 61.8% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 76.2% vs 68.3% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 71.4% vs 59.4% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 52.4% vs 33.4% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 39.5% vs 16.6% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 75% vs 61.8% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 75.5% vs 68.3% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 76.7% vs 59.4% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 62.3% vs 33.4% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 42.1% vs 16.6% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 73.4% vs 61.8% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 73.4% vs 68.3% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 72% vs 59.4% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 55.6% vs 33.4% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 37.2% vs 16.6% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 72.5% vs 29.2% 200 mg QD · wk 12 · n 69 · Phase 2 · primary NCT01894516
  • 68.6% vs 44.2% 200 mg QD · wk 12 · n 86 · Phase 2 · primary NCT01888874
  • 65.7% vs 29.2% 100 mg QD · wk 12 · n 70 · Phase 2 · primary NCT01894516
  • 63.5% vs 44.2% 100 mg QD · wk 12 · n 85 · Phase 2 · primary NCT01888874
  • 78.6% vs 44.2% 100 mg BID · wk 12 · n 84 · Phase 2 · primary NCT01888874
  • 66.7% vs 29.2% 50 mg QD · wk 12 · n 72 · Phase 2 · primary NCT01894516
  • 56.1% vs 44.2% 50 mg QD · wk 12 · n 82 · Phase 2 · primary NCT01888874
  • 60% vs 44.2% 50 mg BID · wk 12 · n 85 · Phase 2 · primary NCT01888874
  • 57% vs 44.2% 25 mg BID · wk 12 · n 86 · Phase 2 · primary NCT01888874
  • 73.3% vs 41.9% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 61.2% vs 41.9% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 79.8% vs 41.9% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 54.9% vs 41.9% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 60% vs 41.9% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 55.8% vs 41.9% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 81% vs 40.9% wk 12 · n 21 · Phase 2 · secondary NCT02885181
—Not posted · NCT06276998
ACR5064.2% vs 66%−1.8 vs placebo200 mg · wk 52 · n 475NCT02889796
87 other results
  • 63.2% vs 63.4% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 57.9% vs 33.3% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 47.2% vs 19.8% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 22.3% vs 5.9% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 9.1% vs 1.1% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 60.6% vs 66% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 57.7% vs 63.4% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 52.7% vs 33.3% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 36.5% vs 19.8% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 12.9% vs 5.9% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 5.8% vs 1.1% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 45.6% vs 18.9% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 42.9% vs 14.9% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 22.4% vs 7.4% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 35.3% vs 18.9% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 32% vs 14.9% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 21.6% vs 7.4% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 61.4% vs 48.3% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 58.6% vs 48.6% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 58.1% vs 45.7% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 45.7% vs 28.4% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 25.7% vs 9.4% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 16.2% vs 2.9% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 62.3% vs 48.3% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 60.6% vs 48.6% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 61.5% vs 45.7% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 53.1% vs 28.4% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 29.3% vs 9.4% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 13% vs 2.9% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 59.4% vs 48.3% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 55.6% vs 48.6% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 57% vs 45.7% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 44.4% vs 28.4% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 20.8% vs 9.4% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 9.2% vs 2.9% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 50% vs 16.3% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 43.5% vs 11.1% 200 mg QD · wk 12 · n 69 · Phase 2 · secondary NCT01894516
  • 43% vs 15.1% 200 mg QD · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 31.9% vs 5.6% 200 mg QD · wk 8 · n 69 · Phase 2 · secondary NCT01894516
  • 33.7% vs 12.8% 200 mg QD · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 23.2% vs 4.2% 200 mg QD · wk 4 · n 69 · Phase 2 · secondary NCT01894516
  • 17.4% vs 7% 200 mg QD · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 21.7% vs 4.2% 200 mg QD · wk 2 · n 69 · Phase 2 · secondary NCT01894516
  • 10.5% vs 5.8% 200 mg QD · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 7.2% vs 1.4% 200 mg QD · wk 1 · n 69 · Phase 2 · secondary NCT01894516
  • 4.7% vs 1.2% 200 mg QD · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 47.1% vs 16.3% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 54.8% vs 16.3% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 37.1% vs 11.1% 100 mg QD · wk 12 · n 70 · Phase 2 · secondary NCT01894516
  • 37.6% vs 15.1% 100 mg QD · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 54.8% vs 15.1% 100 mg BID · wk 12 · n 84 · Phase 2 · secondary NCT01888874
  • 25.7% vs 5.6% 100 mg QD · wk 8 · n 70 · Phase 2 · secondary NCT01894516
  • 35.3% vs 12.8% 100 mg QD · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 45.2% vs 12.8% 100 mg BID · wk 8 · n 84 · Phase 2 · secondary NCT01888874
  • 18.6% vs 4.2% 100 mg QD · wk 4 · n 70 · Phase 2 · secondary NCT01894516
  • 32.9% vs 7% 100 mg QD · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 34.5% vs 7% 100 mg BID · wk 4 · n 84 · Phase 2 · secondary NCT01888874
  • 7.1% vs 4.2% 100 mg QD · wk 2 · n 70 · Phase 2 · secondary NCT01894516
  • 20% vs 5.8% 100 mg QD · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 21.4% vs 5.8% 100 mg BID · wk 2 · n 84 · Phase 2 · secondary NCT01888874
  • 10% vs 1.4% 100 mg QD · wk 1 · n 70 · Phase 2 · secondary NCT01894516
  • 4.7% vs 1.2% 100 mg QD · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 7.1% vs 1.2% 100 mg BID · wk 1 · n 84 · Phase 2 · secondary NCT01888874
  • 35.4% vs 16.3% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 35.3% vs 16.3% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 34.7% vs 11.1% 50 mg QD · wk 12 · n 72 · Phase 2 · secondary NCT01894516
  • 32.9% vs 15.1% 50 mg QD · wk 12 · n 82 · Phase 2 · secondary NCT01888874
  • 34.1% vs 15.1% 50 mg BID · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 16.7% vs 5.6% 50 mg QD · wk 8 · n 72 · Phase 2 · secondary NCT01894516
  • 26.8% vs 12.8% 50 mg QD · wk 8 · n 82 · Phase 2 · secondary NCT01888874
  • 34.1% vs 12.8% 50 mg BID · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 15.3% vs 4.2% 50 mg QD · wk 4 · n 72 · Phase 2 · secondary NCT01894516
  • 13.4% vs 7% 50 mg QD · wk 4 · n 82 · Phase 2 · secondary NCT01888874
  • 18.8% vs 7% 50 mg BID · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 5.6% vs 4.2% 50 mg QD · wk 2 · n 72 · Phase 2 · secondary NCT01894516
  • 7.3% vs 5.8% 50 mg QD · wk 2 · n 82 · Phase 2 · secondary NCT01888874
  • 11.8% vs 5.8% 50 mg BID · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 1.4% vs 1.4% 50 mg QD · wk 1 · n 72 · Phase 2 · secondary NCT01894516
  • 2.4% vs 1.2% 50 mg QD · wk 1 · n 82 · Phase 2 · secondary NCT01888874
  • 7.1% vs 1.2% 50 mg BID · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 34.9% vs 16.3% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 27.9% vs 15.1% 25 mg BID · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 25.6% vs 12.8% 25 mg BID · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 15.1% vs 7% 25 mg BID · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 7% vs 5.8% 25 mg BID · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 3.5% vs 1.2% 25 mg BID · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 47.6% vs 22.7% wk 12 · n 21 · Phase 2 · secondary NCT02885181
—Not posted · NCT06276998
ACR7044.4% vs 37.7%+6.7 vs placebo200 mg · wk 52 · n 475NCT02889796
87 other results
  • 40.2% vs 34.6% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 36.2% vs 14.9% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 26.1% vs 6.7% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 9.1% vs 1.5% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 2.7% vs 0.4% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 39% vs 37.7% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 35.4% vs 34.6% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 29.6% vs 14.9% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 18.5% vs 6.7% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 3.3% vs 1.5% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 1.3% vs 0.4% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 32% vs 8.1% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 21.8% vs 6.8% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 6.1% vs 2.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 20.3% vs 8.1% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 14.4% vs 6.8% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 8.5% vs 2.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 45.2% vs 29.8% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 39.5% vs 32.2% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 40% vs 26% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 29% vs 13.2% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 11.4% vs 3.8% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 4.3% vs 0.7% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 47.8% vs 29.8% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 45.9% vs 32.2% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 43.8% vs 26% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 32.9% vs 13.2% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 13% vs 3.8% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 3.1% vs 0.7% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 40.1% vs 29.8% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 37.2% vs 32.2% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 40.1% vs 26% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 27.1% vs 13.2% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 6.3% vs 3.8% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 1.9% vs 0.7% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 29.1% vs 9.3% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 13% vs 2.8% 200 mg QD · wk 12 · n 69 · Phase 2 · secondary NCT01894516
  • 24.4% vs 8.1% 200 mg QD · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 17.4% vs 2.8% 200 mg QD · wk 8 · n 69 · Phase 2 · secondary NCT01894516
  • 18.6% vs 7% 200 mg QD · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 11.6% vs 1.4% 200 mg QD · wk 4 · n 69 · Phase 2 · secondary NCT01894516
  • 4.7% vs 3.5% 200 mg QD · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 4.3% vs 2.8% 200 mg QD · wk 2 · n 69 · Phase 2 · secondary NCT01894516
  • 5.8% vs 1.2% 200 mg QD · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 1.4% vs 0% 200 mg QD · wk 1 · n 69 · Phase 2 · secondary NCT01894516
  • 1.2% vs 1.2% 200 mg QD · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 32.9% vs 9.3% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 39.3% vs 9.3% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 18.6% vs 2.8% 100 mg QD · wk 12 · n 70 · Phase 2 · secondary NCT01894516
  • 21.2% vs 8.1% 100 mg QD · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 31% vs 8.1% 100 mg BID · wk 12 · n 84 · Phase 2 · secondary NCT01888874
  • 11.4% vs 2.8% 100 mg QD · wk 8 · n 70 · Phase 2 · secondary NCT01894516
  • 23.5% vs 7% 100 mg QD · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 27.4% vs 7% 100 mg BID · wk 8 · n 84 · Phase 2 · secondary NCT01888874
  • 5.7% vs 1.4% 100 mg QD · wk 4 · n 70 · Phase 2 · secondary NCT01894516
  • 14.1% vs 3.5% 100 mg QD · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 10.7% vs 3.5% 100 mg BID · wk 4 · n 84 · Phase 2 · secondary NCT01888874
  • 1.4% vs 2.8% 100 mg QD · wk 2 · n 70 · Phase 2 · secondary NCT01894516
  • 7.1% vs 1.2% 100 mg QD · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 3.6% vs 1.2% 100 mg BID · wk 2 · n 84 · Phase 2 · secondary NCT01888874
  • 1.4% vs 0% 100 mg QD · wk 1 · n 70 · Phase 2 · secondary NCT01894516
  • 0% vs 1.2% 100 mg QD · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 4.8% vs 1.2% 100 mg BID · wk 1 · n 84 · Phase 2 · secondary NCT01888874
  • 22% vs 9.3% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 23.5% vs 9.3% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 8.3% vs 2.8% 50 mg QD · wk 12 · n 72 · Phase 2 · secondary NCT01894516
  • 15.9% vs 8.1% 50 mg QD · wk 12 · n 82 · Phase 2 · secondary NCT01888874
  • 18.8% vs 8.1% 50 mg BID · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 6.9% vs 2.8% 50 mg QD · wk 8 · n 72 · Phase 2 · secondary NCT01894516
  • 11% vs 7% 50 mg QD · wk 8 · n 82 · Phase 2 · secondary NCT01888874
  • 14.1% vs 7% 50 mg BID · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 8.3% vs 1.4% 50 mg QD · wk 4 · n 72 · Phase 2 · secondary NCT01894516
  • 7.3% vs 3.5% 50 mg QD · wk 4 · n 82 · Phase 2 · secondary NCT01888874
  • 9.4% vs 3.5% 50 mg BID · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 1.4% vs 2.8% 50 mg QD · wk 2 · n 72 · Phase 2 · secondary NCT01894516
  • 2.4% vs 1.2% 50 mg QD · wk 2 · n 82 · Phase 2 · secondary NCT01888874
  • 5.9% vs 1.2% 50 mg BID · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 0% vs 0% 50 mg QD · wk 1 · n 72 · Phase 2 · secondary NCT01894516
  • 0% vs 1.2% 50 mg QD · wk 1 · n 82 · Phase 2 · secondary NCT01888874
  • 2.4% vs 1.2% 50 mg BID · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 20.9% vs 9.3% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 14% vs 8.1% 25 mg BID · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 9.3% vs 7% 25 mg BID · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 5.8% vs 3.5% 25 mg BID · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 2.3% vs 1.2% 25 mg BID · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 1.2% vs 1.2% 25 mg BID · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 38.1% vs 13.6% wk 12 · n 21 · Phase 2 · secondary NCT02885181
—Not posted · NCT06276998
DAS28-CRP remission54.5% vs 50.8%+3.7 vs placebo200 mg · wk 52 · n 475NCT02889796
35 other results
  • 50.3% vs 46.1% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 48.4% vs 16.2% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 34.1% vs 9.3% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 13.7% vs 2.9% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 5.1% vs 0.6% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 44.8% vs 50.8% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 42.9% vs 46.1% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 35.2% vs 16.2% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 23.8% vs 9.3% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 8.8% vs 2.9% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 1.7% vs 0.6% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 30.6% vs 12.2% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 22.4% vs 8.1% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 10.2% vs 2.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 26.1% vs 12.2% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 25.5% vs 8.1% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 11.8% vs 2.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 46.2% vs 31.5% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 43.3% vs 34.4% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 42.4% vs 29.1% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 29.5% vs 17.1% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 19.5% vs 4.8% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 10% vs 1% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 53.4% vs 31.5% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 52.6% vs 34.4% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 54.1% vs 29.1% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 39.7% vs 17.1% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 16.6% vs 4.8% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 7.2% vs 1% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 43% vs 31.5% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 42% vs 34.4% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 42.5% vs 29.1% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 31.9% vs 17.1% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 15% vs 4.8% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 4.3% vs 1% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
—Not posted · NCT06276998
HAQ-DI, change-0.9 vs -0.7−0.2 vs placebo200 mg · wk 52 · n 475NCT02889796
36 other results
  • -0.9 vs -0.7 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.6 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • -0.7 vs -0.4 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • -0.4 vs -0.3 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • -0.3 vs -0.1 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.7 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.7 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.6 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • -0.6 vs -0.4 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • -0.3 vs -0.3 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • -0.2 vs -0.1 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.4 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • -0.6 vs -0.2 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • -0.4 vs -0.2 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • -0.6 vs -0.4 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • -0.5 vs -0.2 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • -0.3 vs -0.2 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • -0.9 vs -0.9 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • -0.5 vs -0.3 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • -0.3 vs -0.2 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • -1 vs -0.9 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • -1.0 vs -0.9 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • -0.6 vs -0.3 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • -0.4 vs -0.2 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • -1.0 vs -0.9 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • -0.5 vs -0.3 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • -0.4 vs -0.2 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • -0.7 vs -0.4 wk 12 · n 21 · Phase 2 · secondary NCT02885181
—Not posted · NCT06276998
Modified Sharp score, change0.2 vs 0.9−0.7 vs placebo200 mg · wk 52 · n 468NCT02889796
9 other results
  • 0.1 vs 0.4 200 mg · wk 24 · n 467 · Phase 3 · secondary NCT02889796
  • 0.5 vs 0.9 100 mg · wk 52 · n 472 · Phase 3 · secondary NCT02889796
  • 0.2 vs 0.4 100 mg · wk 24 · n 471 · Phase 3 · secondary NCT02889796
  • 0.3 vs 0.8 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • -0.0 vs 0.5 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 0.3 vs 0.8 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.5 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.8 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.5 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
—Not posted · NCT06276998

ACR20

filgotinib
76.6% vs 49.9%+26.7 vs placebo200 mg · wk 12 · n 475NCT02889796
51 other results
  • 69.8% vs 49.9% 100 mg · wk 12 · n 480 · Phase 3 · primary NCT02889796
  • 66% vs 31.1% 200 mg · wk 12 · n 147 · Phase 3 · primary NCT02873936
  • 57.5% vs 31.1% 100 mg · wk 12 · n 153 · Phase 3 · primary NCT02873936
  • 78.1% vs 71.4% 200 mg · wk 24 · n 210 · Phase 3 · primary NCT02886728
  • 81% vs 71.4% 200 mg · wk 24 · n 416 · Phase 3 · primary NCT02886728
  • 80.2% vs 71.4% 100 mg · wk 24 · n 207 · Phase 3 · primary NCT02886728
  • 82.9% vs 85.9% 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • 82.9% vs 86.9% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 78.1% vs 59.2% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 51.6% vs 31.8% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 37.3% vs 14.9% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 79.6% vs 85.9% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 79.2% vs 86.9% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 77.7% vs 59.2% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 45.6% vs 31.8% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 27.5% vs 14.9% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 69.4% vs 34.5% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 51.7% vs 25.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 54.9% vs 34.5% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 44.4% vs 25.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 74.8% vs 61.8% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 76.2% vs 68.3% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 71.4% vs 59.4% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 52.4% vs 33.4% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 39.5% vs 16.6% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 75% vs 61.8% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 75.5% vs 68.3% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 76.7% vs 59.4% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 62.3% vs 33.4% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 42.1% vs 16.6% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 73.4% vs 61.8% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 73.4% vs 68.3% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 72% vs 59.4% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 55.6% vs 33.4% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 37.2% vs 16.6% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 72.5% vs 29.2% 200 mg QD · wk 12 · n 69 · Phase 2 · primary NCT01894516
  • 68.6% vs 44.2% 200 mg QD · wk 12 · n 86 · Phase 2 · primary NCT01888874
  • 65.7% vs 29.2% 100 mg QD · wk 12 · n 70 · Phase 2 · primary NCT01894516
  • 63.5% vs 44.2% 100 mg QD · wk 12 · n 85 · Phase 2 · primary NCT01888874
  • 78.6% vs 44.2% 100 mg BID · wk 12 · n 84 · Phase 2 · primary NCT01888874
  • 66.7% vs 29.2% 50 mg QD · wk 12 · n 72 · Phase 2 · primary NCT01894516
  • 56.1% vs 44.2% 50 mg QD · wk 12 · n 82 · Phase 2 · primary NCT01888874
  • 60% vs 44.2% 50 mg BID · wk 12 · n 85 · Phase 2 · primary NCT01888874
  • 57% vs 44.2% 25 mg BID · wk 12 · n 86 · Phase 2 · primary NCT01888874
  • 73.3% vs 41.9% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 61.2% vs 41.9% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 79.8% vs 41.9% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 54.9% vs 41.9% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 60% vs 41.9% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 55.8% vs 41.9% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 81% vs 40.9% wk 12 · n 21 · Phase 2 · secondary NCT02885181
Zemprocitinib
—Not posted · NCT06276998

ACR50

filgotinib
64.2% vs 66%−1.8 vs placebo200 mg · wk 52 · n 475NCT02889796
87 other results
  • 63.2% vs 63.4% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 57.9% vs 33.3% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 47.2% vs 19.8% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 22.3% vs 5.9% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 9.1% vs 1.1% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 60.6% vs 66% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 57.7% vs 63.4% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 52.7% vs 33.3% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 36.5% vs 19.8% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 12.9% vs 5.9% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 5.8% vs 1.1% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 45.6% vs 18.9% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 42.9% vs 14.9% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 22.4% vs 7.4% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 35.3% vs 18.9% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 32% vs 14.9% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 21.6% vs 7.4% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 61.4% vs 48.3% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 58.6% vs 48.6% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 58.1% vs 45.7% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 45.7% vs 28.4% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 25.7% vs 9.4% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 16.2% vs 2.9% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 62.3% vs 48.3% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 60.6% vs 48.6% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 61.5% vs 45.7% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 53.1% vs 28.4% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 29.3% vs 9.4% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 13% vs 2.9% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 59.4% vs 48.3% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 55.6% vs 48.6% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 57% vs 45.7% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 44.4% vs 28.4% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 20.8% vs 9.4% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 9.2% vs 2.9% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 50% vs 16.3% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 43.5% vs 11.1% 200 mg QD · wk 12 · n 69 · Phase 2 · secondary NCT01894516
  • 43% vs 15.1% 200 mg QD · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 31.9% vs 5.6% 200 mg QD · wk 8 · n 69 · Phase 2 · secondary NCT01894516
  • 33.7% vs 12.8% 200 mg QD · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 23.2% vs 4.2% 200 mg QD · wk 4 · n 69 · Phase 2 · secondary NCT01894516
  • 17.4% vs 7% 200 mg QD · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 21.7% vs 4.2% 200 mg QD · wk 2 · n 69 · Phase 2 · secondary NCT01894516
  • 10.5% vs 5.8% 200 mg QD · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 7.2% vs 1.4% 200 mg QD · wk 1 · n 69 · Phase 2 · secondary NCT01894516
  • 4.7% vs 1.2% 200 mg QD · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 47.1% vs 16.3% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 54.8% vs 16.3% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 37.1% vs 11.1% 100 mg QD · wk 12 · n 70 · Phase 2 · secondary NCT01894516
  • 37.6% vs 15.1% 100 mg QD · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 54.8% vs 15.1% 100 mg BID · wk 12 · n 84 · Phase 2 · secondary NCT01888874
  • 25.7% vs 5.6% 100 mg QD · wk 8 · n 70 · Phase 2 · secondary NCT01894516
  • 35.3% vs 12.8% 100 mg QD · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 45.2% vs 12.8% 100 mg BID · wk 8 · n 84 · Phase 2 · secondary NCT01888874
  • 18.6% vs 4.2% 100 mg QD · wk 4 · n 70 · Phase 2 · secondary NCT01894516
  • 32.9% vs 7% 100 mg QD · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 34.5% vs 7% 100 mg BID · wk 4 · n 84 · Phase 2 · secondary NCT01888874
  • 7.1% vs 4.2% 100 mg QD · wk 2 · n 70 · Phase 2 · secondary NCT01894516
  • 20% vs 5.8% 100 mg QD · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 21.4% vs 5.8% 100 mg BID · wk 2 · n 84 · Phase 2 · secondary NCT01888874
  • 10% vs 1.4% 100 mg QD · wk 1 · n 70 · Phase 2 · secondary NCT01894516
  • 4.7% vs 1.2% 100 mg QD · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 7.1% vs 1.2% 100 mg BID · wk 1 · n 84 · Phase 2 · secondary NCT01888874
  • 35.4% vs 16.3% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 35.3% vs 16.3% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 34.7% vs 11.1% 50 mg QD · wk 12 · n 72 · Phase 2 · secondary NCT01894516
  • 32.9% vs 15.1% 50 mg QD · wk 12 · n 82 · Phase 2 · secondary NCT01888874
  • 34.1% vs 15.1% 50 mg BID · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 16.7% vs 5.6% 50 mg QD · wk 8 · n 72 · Phase 2 · secondary NCT01894516
  • 26.8% vs 12.8% 50 mg QD · wk 8 · n 82 · Phase 2 · secondary NCT01888874
  • 34.1% vs 12.8% 50 mg BID · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 15.3% vs 4.2% 50 mg QD · wk 4 · n 72 · Phase 2 · secondary NCT01894516
  • 13.4% vs 7% 50 mg QD · wk 4 · n 82 · Phase 2 · secondary NCT01888874
  • 18.8% vs 7% 50 mg BID · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 5.6% vs 4.2% 50 mg QD · wk 2 · n 72 · Phase 2 · secondary NCT01894516
  • 7.3% vs 5.8% 50 mg QD · wk 2 · n 82 · Phase 2 · secondary NCT01888874
  • 11.8% vs 5.8% 50 mg BID · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 1.4% vs 1.4% 50 mg QD · wk 1 · n 72 · Phase 2 · secondary NCT01894516
  • 2.4% vs 1.2% 50 mg QD · wk 1 · n 82 · Phase 2 · secondary NCT01888874
  • 7.1% vs 1.2% 50 mg BID · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 34.9% vs 16.3% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 27.9% vs 15.1% 25 mg BID · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 25.6% vs 12.8% 25 mg BID · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 15.1% vs 7% 25 mg BID · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 7% vs 5.8% 25 mg BID · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 3.5% vs 1.2% 25 mg BID · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 47.6% vs 22.7% wk 12 · n 21 · Phase 2 · secondary NCT02885181
Zemprocitinib
—Not posted · NCT06276998

ACR70

filgotinib
44.4% vs 37.7%+6.7 vs placebo200 mg · wk 52 · n 475NCT02889796
87 other results
  • 40.2% vs 34.6% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 36.2% vs 14.9% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 26.1% vs 6.7% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 9.1% vs 1.5% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 2.7% vs 0.4% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 39% vs 37.7% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 35.4% vs 34.6% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 29.6% vs 14.9% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 18.5% vs 6.7% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 3.3% vs 1.5% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 1.3% vs 0.4% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 32% vs 8.1% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 21.8% vs 6.8% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 6.1% vs 2.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 20.3% vs 8.1% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 14.4% vs 6.8% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 8.5% vs 2.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 45.2% vs 29.8% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 39.5% vs 32.2% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 40% vs 26% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 29% vs 13.2% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 11.4% vs 3.8% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 4.3% vs 0.7% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 47.8% vs 29.8% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 45.9% vs 32.2% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 43.8% vs 26% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 32.9% vs 13.2% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 13% vs 3.8% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 3.1% vs 0.7% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 40.1% vs 29.8% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 37.2% vs 32.2% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 40.1% vs 26% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 27.1% vs 13.2% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 6.3% vs 3.8% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 1.9% vs 0.7% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 29.1% vs 9.3% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 13% vs 2.8% 200 mg QD · wk 12 · n 69 · Phase 2 · secondary NCT01894516
  • 24.4% vs 8.1% 200 mg QD · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 17.4% vs 2.8% 200 mg QD · wk 8 · n 69 · Phase 2 · secondary NCT01894516
  • 18.6% vs 7% 200 mg QD · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 11.6% vs 1.4% 200 mg QD · wk 4 · n 69 · Phase 2 · secondary NCT01894516
  • 4.7% vs 3.5% 200 mg QD · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 4.3% vs 2.8% 200 mg QD · wk 2 · n 69 · Phase 2 · secondary NCT01894516
  • 5.8% vs 1.2% 200 mg QD · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 1.4% vs 0% 200 mg QD · wk 1 · n 69 · Phase 2 · secondary NCT01894516
  • 1.2% vs 1.2% 200 mg QD · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 32.9% vs 9.3% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 39.3% vs 9.3% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 18.6% vs 2.8% 100 mg QD · wk 12 · n 70 · Phase 2 · secondary NCT01894516
  • 21.2% vs 8.1% 100 mg QD · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 31% vs 8.1% 100 mg BID · wk 12 · n 84 · Phase 2 · secondary NCT01888874
  • 11.4% vs 2.8% 100 mg QD · wk 8 · n 70 · Phase 2 · secondary NCT01894516
  • 23.5% vs 7% 100 mg QD · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 27.4% vs 7% 100 mg BID · wk 8 · n 84 · Phase 2 · secondary NCT01888874
  • 5.7% vs 1.4% 100 mg QD · wk 4 · n 70 · Phase 2 · secondary NCT01894516
  • 14.1% vs 3.5% 100 mg QD · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 10.7% vs 3.5% 100 mg BID · wk 4 · n 84 · Phase 2 · secondary NCT01888874
  • 1.4% vs 2.8% 100 mg QD · wk 2 · n 70 · Phase 2 · secondary NCT01894516
  • 7.1% vs 1.2% 100 mg QD · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 3.6% vs 1.2% 100 mg BID · wk 2 · n 84 · Phase 2 · secondary NCT01888874
  • 1.4% vs 0% 100 mg QD · wk 1 · n 70 · Phase 2 · secondary NCT01894516
  • 0% vs 1.2% 100 mg QD · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 4.8% vs 1.2% 100 mg BID · wk 1 · n 84 · Phase 2 · secondary NCT01888874
  • 22% vs 9.3% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 23.5% vs 9.3% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 8.3% vs 2.8% 50 mg QD · wk 12 · n 72 · Phase 2 · secondary NCT01894516
  • 15.9% vs 8.1% 50 mg QD · wk 12 · n 82 · Phase 2 · secondary NCT01888874
  • 18.8% vs 8.1% 50 mg BID · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 6.9% vs 2.8% 50 mg QD · wk 8 · n 72 · Phase 2 · secondary NCT01894516
  • 11% vs 7% 50 mg QD · wk 8 · n 82 · Phase 2 · secondary NCT01888874
  • 14.1% vs 7% 50 mg BID · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 8.3% vs 1.4% 50 mg QD · wk 4 · n 72 · Phase 2 · secondary NCT01894516
  • 7.3% vs 3.5% 50 mg QD · wk 4 · n 82 · Phase 2 · secondary NCT01888874
  • 9.4% vs 3.5% 50 mg BID · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 1.4% vs 2.8% 50 mg QD · wk 2 · n 72 · Phase 2 · secondary NCT01894516
  • 2.4% vs 1.2% 50 mg QD · wk 2 · n 82 · Phase 2 · secondary NCT01888874
  • 5.9% vs 1.2% 50 mg BID · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 0% vs 0% 50 mg QD · wk 1 · n 72 · Phase 2 · secondary NCT01894516
  • 0% vs 1.2% 50 mg QD · wk 1 · n 82 · Phase 2 · secondary NCT01888874
  • 2.4% vs 1.2% 50 mg BID · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 20.9% vs 9.3% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 14% vs 8.1% 25 mg BID · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 9.3% vs 7% 25 mg BID · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 5.8% vs 3.5% 25 mg BID · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 2.3% vs 1.2% 25 mg BID · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 1.2% vs 1.2% 25 mg BID · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 38.1% vs 13.6% wk 12 · n 21 · Phase 2 · secondary NCT02885181
Zemprocitinib
—Not posted · NCT06276998

DAS28-CRP remission

filgotinib
54.5% vs 50.8%+3.7 vs placebo200 mg · wk 52 · n 475NCT02889796
35 other results
  • 50.3% vs 46.1% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 48.4% vs 16.2% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 34.1% vs 9.3% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 13.7% vs 2.9% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 5.1% vs 0.6% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 44.8% vs 50.8% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 42.9% vs 46.1% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 35.2% vs 16.2% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 23.8% vs 9.3% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 8.8% vs 2.9% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 1.7% vs 0.6% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 30.6% vs 12.2% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 22.4% vs 8.1% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 10.2% vs 2.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 26.1% vs 12.2% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 25.5% vs 8.1% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 11.8% vs 2.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 46.2% vs 31.5% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 43.3% vs 34.4% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 42.4% vs 29.1% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 29.5% vs 17.1% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 19.5% vs 4.8% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 10% vs 1% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 53.4% vs 31.5% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 52.6% vs 34.4% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 54.1% vs 29.1% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 39.7% vs 17.1% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 16.6% vs 4.8% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 7.2% vs 1% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 43% vs 31.5% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 42% vs 34.4% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 42.5% vs 29.1% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 31.9% vs 17.1% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 15% vs 4.8% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 4.3% vs 1% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
Zemprocitinib
—Not posted · NCT06276998

HAQ-DI, change

filgotinib
-0.9 vs -0.7−0.2 vs placebo200 mg · wk 52 · n 475NCT02889796
36 other results
  • -0.9 vs -0.7 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.6 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • -0.7 vs -0.4 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • -0.4 vs -0.3 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • -0.3 vs -0.1 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.7 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.7 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.6 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • -0.6 vs -0.4 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • -0.3 vs -0.3 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • -0.2 vs -0.1 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.4 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • -0.6 vs -0.2 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • -0.4 vs -0.2 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • -0.6 vs -0.4 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • -0.5 vs -0.2 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • -0.3 vs -0.2 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • -0.9 vs -0.9 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • -0.5 vs -0.3 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • -0.3 vs -0.2 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • -1 vs -0.9 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • -1.0 vs -0.9 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • -0.6 vs -0.3 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • -0.4 vs -0.2 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • -1.0 vs -0.9 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • -0.5 vs -0.3 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • -0.4 vs -0.2 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • -0.7 vs -0.4 wk 12 · n 21 · Phase 2 · secondary NCT02885181
Zemprocitinib
—Not posted · NCT06276998

Modified Sharp score, change

filgotinib
0.2 vs 0.9−0.7 vs placebo200 mg · wk 52 · n 468NCT02889796
9 other results
  • 0.1 vs 0.4 200 mg · wk 24 · n 467 · Phase 3 · secondary NCT02889796
  • 0.5 vs 0.9 100 mg · wk 52 · n 472 · Phase 3 · secondary NCT02889796
  • 0.2 vs 0.4 100 mg · wk 24 · n 471 · Phase 3 · secondary NCT02889796
  • 0.3 vs 0.8 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • -0.0 vs 0.5 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 0.3 vs 0.8 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.5 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.8 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.5 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
Zemprocitinib
—Not posted · NCT06276998
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Zemprocitinib: no structured comparison results are available for Rheumatoid Arthritis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. filgotinib: 4 of 4 rows · Zemprocitinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfilgotinib
Dropout rate
8.8%200 mga
NCT02873936 · Phase 3
show 26 more results
15%100 mg
NCT02873936 · Phase 3
17.1%200 mg
NCT02886728 · Phase 3 · monotherapy
17.3%200 mg
NCT02886728 · Phase 3 · combination
15.5%100 mg
NCT02886728 · Phase 3 · combination
11.1%200 mg
NCT02889796 · Phase 3
12.1%100 mg
NCT02889796 · Phase 3
52.1%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
53%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
53.7%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
61.6%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
0%Filgonitib
NCT03926195 · Phase 2 · registry result, not featured evidence
67.6%Filgotinib Darwin 1
NCT02065700 · Phase 2 · registry result, not featured evidence
66.5%Filgotinib Darwin 2
NCT02065700 · Phase 2 · registry result, not featured evidence
0%
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
4.3%200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
4.3%100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
6.9%50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
7%200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
1.2%100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
8.2%100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
5.9%50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
7.3%50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
10.5%25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
2%200 mga
NCT02873936 · Phase 3
show 26 more results
3.3%100 mg
NCT02873936 · Phase 3
2.4%200 mg
NCT02886728 · Phase 3 · monotherapy
3.1%200 mg
NCT02886728 · Phase 3 · combination
2.4%100 mg
NCT02886728 · Phase 3 · combination
3.6%200 mg
NCT02889796 · Phase 3
1.7%100 mg
NCT02889796 · Phase 3
12.3%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
13.4%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
14%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
12.2%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—Filgonitib
NCT03926195 · Phase 2 · registry result, not featured evidence
33.2%Filgotinib Darwin 1
NCT02065700 · Phase 2 · registry result, not featured evidence
42.6%Filgotinib Darwin 2
NCT02065700 · Phase 2 · registry result, not featured evidence
0%
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
1.4%200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
0%100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
0%50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
1.2%200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
0%100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
3.5%100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
1.2%50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
2.4%50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
3.5%25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
Serious AEs
4.1%200 mga
NCT02873936 · Phase 3
show 26 more results
5.2%100 mg
NCT02873936 · Phase 3
8.1%200 mg
NCT02886728 · Phase 3 · monotherapy
6.3%200 mg
NCT02886728 · Phase 3 · combination
6.3%100 mg
NCT02886728 · Phase 3 · combination
7.4%200 mg
NCT02889796 · Phase 3
8.3%100 mg
NCT02889796 · Phase 3
24.1%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
22.1%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
24.6%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
25.9%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
3.7%200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
12.8%200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
14.3%200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—Filgonitib
NCT03926195 · Phase 2 · registry result, not featured evidence
16.9%Filgotinib Darwin 1
NCT02065700 · Phase 2 · registry result, not featured evidence
19.8%Filgotinib Darwin 2
NCT02065700 · Phase 2 · registry result, not featured evidence
0%
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
4.3%200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
3.5%100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
2.8%50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
2.3%200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
3.6%100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
3.4%100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
0%50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
0%50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
2.3%25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
200 mga
nasopharyngitis 10.2% (placebo 4.7%)
bronchitis 5.4% (placebo 5.4%)
headache 5.4% (placebo 1.4%)
NCT02873936 · Phase 3
show 25 more results
100 mg
headache 5.9% (placebo 1.4%)
nasopharyngitis 5.9% (placebo 4.7%)
upper respiratory tract infection 5.9% (placebo 4.1%)
NCT02873936 · Phase 3
200 mg
nasopharyngitis 8.1%
hypertension 7.1%
nausea 7.1%
NCT02886728 · Phase 3 · monotherapy
200 mg
nausea 12.3%
upper respiratory tract infection 10.1%
alanine aminotransferase increased 5.5%
NCT02886728 · Phase 3 · combination
100 mg
nausea 16.9%
nasopharyngitis 8.2%
alopecia 7.2%
NCT02886728 · Phase 3 · combination
200 mg
nasopharyngitis 9.1% (placebo 5.3%)
upper respiratory tract infection 8.6% (placebo 2.9%)
nausea 5.5% (placebo 1.5%)
NCT02889796 · Phase 3
100 mg
upper respiratory tract infection 10.2% (placebo 2.9%)
nasopharyngitis 10% (placebo 5.3%)
alanine aminotransferase increased 5.2% (placebo 2.3%)
NCT02889796 · Phase 3
200 mg
covid-19 18.3%
nasopharyngitis 13.1%
upper respiratory tract infection 11%
NCT03025308 · Phase 3 · registry result, not featured evidence
200 mg
covid-19 17.3%
upper respiratory tract infection 13.1%
rheumatoid arthritis 11.9%
NCT03025308 · Phase 3 · registry result, not featured evidence
100 mg
covid-19 15.3%
nasopharyngitis 15.1%
rheumatoid arthritis 13.9%
NCT03025308 · Phase 3 · registry result, not featured evidence
100 mg
covid-19 18.5%
rheumatoid arthritis 12.2%
upper respiratory tract infection 11.9%
NCT03025308 · Phase 3 · registry result, not featured evidence
200 mg
nasopharyngitis 7.4% (placebo 7.3%)
dyslipidaemia 3.7% (placebo 0%)
headache 3.7% (placebo 1.8%)
NCT03926195 · Phase 2 · registry result, not featured evidence
200 mg
covid-19 15.4% (placebo 0%)
ankylosing spondylitis 7.7% (placebo 0%)
latent tuberculosis 7.7% (placebo 0%)
NCT03926195 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 57.1% (placebo 7.3%)
covid-19 42.9% (placebo 0%)
alanine aminotransferase increased 14.3% (placebo 0%)
NCT03926195 · Phase 2 · registry result, not featured evidence
hypertension 15.1%
urinary tract infection 14.5%
nasopharyngitis 14.1%
NCT02065700 · Phase 2 · registry result, not featured evidence
mycobacterium tuberculosis complex test positive 16.5%
upper respiratory tract infection 15.3%
hypercholesterolaemia 12.4%
NCT02065700 · Phase 2 · registry result, not featured evidence
asthenia 9.5% (placebo 0%)
blood creatine phosphokinase increased 4.8% (placebo 0%)
dyspepsia 4.8% (placebo 0%)
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
200 mg QD
anaemia 5.8% (placebo 0%)
upper respiratory tract infection 5.8% (placebo 2.8%)
urinary tract infection 5.8% (placebo 1.4%)
NCT01894516 · Phase 2 · registry result, not featured evidence
100 mg QD
urinary tract infection 8.2% (placebo 1.4%)
hypercholesterolaemia 5.9% (placebo 4.2%)
hypertriglyceridaemia 5.9% (placebo 1.4%)
NCT01894516 · Phase 2 · registry result, not featured evidence
50 mg QD
headache 5.6% (placebo 1.4%)
hypercholesterolaemia 5.6% (placebo 4.2%)
hypertension 4.2% (placebo 5.6%)
NCT01894516 · Phase 2 · registry result, not featured evidence
200 mg QD
headache 7% (placebo 4.7%)
hypercholesterolaemia 5.8% (placebo 0%)
hypertension 4.7% (placebo 2.3%)
NCT01888874 · Phase 2 · registry result, not featured evidence
100 mg BID
hypercholesterolaemia 4.8% (placebo 0%)
nasopharyngitis 4.8% (placebo 4.7%)
headache 2.4% (placebo 4.7%)
NCT01888874 · Phase 2 · registry result, not featured evidence
100 mg QD
hypertension 5% (placebo 2.3%)
nasopharyngitis 2.5% (placebo 4.7%)
upper respiratory tract infection 1.7% (placebo 1.2%)
NCT01888874 · Phase 2 · registry result, not featured evidence
50 mg BID
upper respiratory tract infection 5.1% (placebo 1.2%)
vomiting 5.1% (placebo 1.2%)
hypertension 3.4% (placebo 2.3%)
NCT01888874 · Phase 2 · registry result, not featured evidence
50 mg QD
nasopharyngitis 9.8% (placebo 4.7%)
nausea 8.5% (placebo 3.5%)
hypertension 3.7% (placebo 2.3%)
NCT01888874 · Phase 2 · registry result, not featured evidence
25 mg BID
headache 7% (placebo 4.7%)
gastroenteritis 5.8% (placebo 0%)
nasopharyngitis 4.7% (placebo 4.7%)
NCT01888874 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

filgotinib

ACR20 66% (n=147) vs 31.1% (n=148) placebo @ 12wk200 mg
responder rate · % of participants
NCT02873936 · Phase 3
show 51 more results
51.7% (n=147) vs 25.7% (n=148) placebo @ 4wk200 mg
NCT02873936 · Phase 3
69.4% (n=147) vs 34.5% (n=148) placebo @ 24wk200 mg
NCT02873936 · Phase 3
78.1% (n=210) vs 71.4% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
39.5% (n=210) vs 16.6% (n=416) MTX @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
52.4% (n=210) vs 33.4% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
71.4% (n=210) vs 59.4% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
76.2% (n=210) vs 68.3% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
74.8% (n=210) vs 61.8% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
76.6% (n=475) vs 49.9% (n=475) placebo @ 12wk200 mg
NCT02889796 · Phase 3
37.3% (n=475) vs 14.9% (n=475) placebo @ 2wk200 mg
NCT02889796 · Phase 3
51.6% (n=475) vs 31.8% (n=475) placebo @ 4wk200 mg
NCT02889796 · Phase 3
78.1% (n=475) vs 59.2% (n=475) placebo @ 24wk200 mg
NCT02889796 · Phase 3
82.9% (n=475) vs 90.5% (n=190) placebo @ 36wk200 mg
NCT02889796 · Phase 3
82.9% (n=475) vs 86.3% (n=190) placebo @ 52wk200 mg
NCT02889796 · Phase 3
72.5% (n=69) vs 29.2% (n=72) placebo @ 12wk200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
68.6% (n=86) vs 44.2% (n=86) placebo @ 12wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
73.3% (n=86) vs 41.9% (n=86) placebo @ 24wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
57.5% (n=153) vs 31.1% (n=148) placebo @ 12wk100 mg
NCT02873936 · Phase 3
44.4% (n=153) vs 25.7% (n=148) placebo @ 4wk100 mg
NCT02873936 · Phase 3
54.9% (n=153) vs 34.5% (n=148) placebo @ 24wk100 mg
NCT02873936 · Phase 3
69.8% (n=480) vs 49.9% (n=475) placebo @ 12wk100 mg
NCT02889796 · Phase 3
27.5% (n=480) vs 14.9% (n=475) placebo @ 2wk100 mg
NCT02889796 · Phase 3
45.6% (n=480) vs 31.8% (n=475) placebo @ 4wk100 mg
NCT02889796 · Phase 3
77.7% (n=480) vs 59.2% (n=475) placebo @ 24wk100 mg
NCT02889796 · Phase 3
79.2% (n=480) vs 90.5% (n=190) placebo @ 36wk100 mg
NCT02889796 · Phase 3
79.6% (n=480) vs 86.3% (n=190) placebo @ 52wk100 mg
NCT02889796 · Phase 3
65.7% (n=70) vs 29.2% (n=72) placebo @ 12wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
63.5% (n=85) vs 44.2% (n=86) placebo @ 12wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
78.6% (n=84) vs 44.2% (n=86) placebo @ 12wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
61.2% (n=85) vs 41.9% (n=86) placebo @ 24wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
79.8% (n=84) vs 41.9% (n=86) placebo @ 24wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
81% (n=416) vs 71.4% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · combination
42.1% (n=416) vs 16.6% (n=416) MTX @ 2wk200 mg
NCT02886728 · Phase 3 · combination
62.3% (n=416) vs 33.4% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · combination
76.7% (n=416) vs 59.4% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · combination
75.5% (n=416) vs 68.3% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · combination
75% (n=416) vs 61.8% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · combination
80.2% (n=207) vs 71.4% (n=416) MTX @ 24wk100 mg
NCT02886728 · Phase 3 · combination
37.2% (n=207) vs 16.6% (n=416) MTX @ 2wk100 mg
NCT02886728 · Phase 3 · combination
55.6% (n=207) vs 33.4% (n=416) MTX @ 4wk100 mg
NCT02886728 · Phase 3 · combination
72% (n=207) vs 59.4% (n=416) MTX @ 12wk100 mg
NCT02886728 · Phase 3 · combination
73.4% (n=207) vs 68.3% (n=416) MTX @ 36wk100 mg
NCT02886728 · Phase 3 · combination
73.4% (n=207) vs 61.8% (n=416) MTX @ 52wk100 mg
NCT02886728 · Phase 3 · combination
66.7% (n=72) vs 29.2% (n=72) placebo @ 12wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
56.1% (n=82) vs 44.2% (n=86) placebo @ 12wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
60% (n=85) vs 44.2% (n=86) placebo @ 12wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
54.9% (n=82) vs 41.9% (n=86) placebo @ 24wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
60% (n=85) vs 41.9% (n=86) placebo @ 24wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
57% (n=86) vs 44.2% (n=86) placebo @ 12wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
55.8% (n=86) vs 41.9% (n=86) placebo @ 24wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
81% (n=21) vs 40.9% (n=22) placebo @ 12wk
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
HAQ-DI -0.55 vs -0.23 placebo score @ 12wk200 mg
absolute change · score
NCT02873936 · Phase 3
show 36 more results
-0.39 vs -0.18 placebo score @ 4wk200 mg
NCT02873936 · Phase 3
-0.75 vs -0.42 placebo score @ 24wk200 mg
NCT02873936 · Phase 3
-0.89 vs -0.79 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
-0.32 vs -0.18 MTX score @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
-0.51 vs -0.32 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
-0.76 vs -0.61 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
-0.91 vs -0.89 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
-0.95 vs -0.88 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
-0.69 vs -0.42 placebo score @ 12wk200 mg
NCT02889796 · Phase 3
-0.3 vs -0.15 placebo score @ 2wk200 mg
NCT02889796 · Phase 3
-0.43 vs -0.26 placebo score @ 4wk200 mg
NCT02889796 · Phase 3
-0.82 vs -0.62 placebo score @ 24wk200 mg
NCT02889796 · Phase 3
-0.88 vs -0.96 placebo score @ 36wk200 mg
NCT02889796 · Phase 3
-0.93 vs -0.99 placebo score @ 52wk200 mg
NCT02889796 · Phase 3
-0.48 vs -0.23 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
-0.32 vs -0.18 placebo score @ 4wk100 mg
NCT02873936 · Phase 3
-0.6 vs -0.42 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
-0.56 vs -0.42 placebo score @ 12wk100 mg
NCT02889796 · Phase 3
-0.22 vs -0.15 placebo score @ 2wk100 mg
NCT02889796 · Phase 3
-0.33 vs -0.26 placebo score @ 4wk100 mg
NCT02889796 · Phase 3
-0.75 vs -0.62 placebo score @ 24wk100 mg
NCT02889796 · Phase 3
-0.8 vs -0.96 placebo score @ 36wk100 mg
NCT02889796 · Phase 3
-0.85 vs -0.99 placebo score @ 52wk100 mg
NCT02889796 · Phase 3
-0.94 vs -0.79 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · combination
-0.37 vs -0.18 MTX score @ 2wk200 mg
NCT02886728 · Phase 3 · combination
-0.57 vs -0.32 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · combination
-0.85 vs -0.61 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · combination
-0.96 vs -0.89 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · combination
-1 vs -0.88 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-0.9 vs -0.79 MTX score @ 24wk100 mg
NCT02886728 · Phase 3 · combination
-0.36 vs -0.18 MTX score @ 2wk100 mg
NCT02886728 · Phase 3 · combination
-0.45 vs -0.32 MTX score @ 4wk100 mg
NCT02886728 · Phase 3 · combination
-0.77 vs -0.61 MTX score @ 12wk100 mg
NCT02886728 · Phase 3 · combination
-0.93 vs -0.89 MTX score @ 36wk100 mg
NCT02886728 · Phase 3 · combination
-0.97 vs -0.88 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
-0.7 vs -0.39 placebo score @ 12wk
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
DAS Low Disease Activity 40.8% (n=147) vs 15.5% (n=148) placebo @ 12wk200 mg
responder rate · % of participants
NCT02873936 · Phase 3
show 29 more results
21.8% (n=147) vs 9.5% (n=148) placebo @ 4wk200 mg
NCT02873936 · Phase 3
48.3% (n=147) vs 20.9% (n=148) placebo @ 24wk200 mg
NCT02873936 · Phase 3
31.9% (n=210) vs 12% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
48.1% (n=210) vs 28.6% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
60% (n=210) vs 46.2% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
65.7% (n=210) vs 47.6% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
49.7% (n=475) vs 23.4% (n=475) placebo @ 12wk200 mg
NCT02889796 · Phase 3
13.1% (n=475) vs 3.6% (n=475) placebo @ 2wk200 mg
NCT02889796 · Phase 3
25.5% (n=475) vs 9.3% (n=475) placebo @ 4wk200 mg
NCT02889796 · Phase 3
60.6% (n=475) vs 33.7% (n=475) placebo @ 24wk200 mg
NCT02889796 · Phase 3
67.4% (n=475) vs 74.7% (n=190) placebo @ 36wk200 mg
NCT02889796 · Phase 3
68.2% (n=475) vs 69.5% (n=190) placebo @ 52wk200 mg
NCT02889796 · Phase 3
37.3% (n=153) vs 15.5% (n=148) placebo @ 12wk100 mg
NCT02873936 · Phase 3
22.2% (n=153) vs 9.5% (n=148) placebo @ 4wk100 mg
NCT02873936 · Phase 3
37.9% (n=153) vs 20.9% (n=148) placebo @ 24wk100 mg
NCT02873936 · Phase 3
38.8% (n=480) vs 23.4% (n=475) placebo @ 12wk100 mg
NCT02889796 · Phase 3
8.1% (n=480) vs 3.6% (n=475) placebo @ 2wk100 mg
NCT02889796 · Phase 3
20.4% (n=480) vs 9.3% (n=475) placebo @ 4wk100 mg
NCT02889796 · Phase 3
53.1% (n=480) vs 33.7% (n=475) placebo @ 24wk100 mg
NCT02889796 · Phase 3
60.2% (n=480) vs 74.7% (n=190) placebo @ 36wk100 mg
NCT02889796 · Phase 3
62.1% (n=480) vs 69.5% (n=190) placebo @ 52wk100 mg
NCT02889796 · Phase 3
30.8% (n=416) vs 12% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · combination
55.8% (n=416) vs 28.6% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · combination
68.8% (n=416) vs 46.2% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · combination
69% (n=416) vs 47.6% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · combination
23.7% (n=207) vs 12% (n=416) MTX @ 4wk100 mg
NCT02886728 · Phase 3 · combination
50.2% (n=207) vs 28.6% (n=416) MTX @ 12wk100 mg
NCT02886728 · Phase 3 · combination
62.8% (n=207) vs 46.2% (n=416) MTX @ 24wk100 mg
NCT02886728 · Phase 3 · combination
59.9% (n=207) vs 47.6% (n=416) MTX @ 52wk100 mg
NCT02886728 · Phase 3 · combination
SF-36 PCS 7.6 vs 3.6 placebo score @ 12wk200 mg
absolute change · score
NCT02873936 · Phase 3
show 30 more results
5.1 vs 2.5 placebo score @ 4wk200 mg
NCT02873936 · Phase 3
9.4 vs 6.6 placebo score @ 24wk200 mg
NCT02873936 · Phase 3
10.4 vs 9.7 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
5.9 vs 3.8 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
8.9 vs 7.6 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
11.2 vs 11.3 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
11.9 vs 11.2 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
9.2 vs 5.8 placebo score @ 12wk200 mg
NCT02889796 · Phase 3
5.6 vs 3.1 placebo score @ 4wk200 mg
NCT02889796 · Phase 3
10.4 vs 7.7 placebo score @ 24wk200 mg
NCT02889796 · Phase 3
11.6 vs 12.9 placebo score @ 36wk200 mg
NCT02889796 · Phase 3
12 vs 13 placebo score @ 52wk200 mg
NCT02889796 · Phase 3
6.8 vs 3.6 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
4.5 vs 2.5 placebo score @ 4wk100 mg
NCT02873936 · Phase 3
9 vs 6.6 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
8.5 vs 5.8 placebo score @ 12wk100 mg
NCT02889796 · Phase 3
4.6 vs 3.1 placebo score @ 4wk100 mg
NCT02889796 · Phase 3
10.3 vs 7.7 placebo score @ 24wk100 mg
NCT02889796 · Phase 3
11 vs 12.9 placebo score @ 36wk100 mg
NCT02889796 · Phase 3
11.5 vs 13 placebo score @ 52wk100 mg
NCT02889796 · Phase 3
12.3 vs 9.7 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · combination
6.8 vs 3.8 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · combination
11.2 vs 7.6 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · combination
12.4 vs 11.3 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · combination
13.4 vs 11.2 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
11.1 vs 9.7 MTX score @ 24wk100 mg
NCT02886728 · Phase 3 · combination
5.3 vs 3.8 MTX score @ 4wk100 mg
NCT02886728 · Phase 3 · combination
9.1 vs 7.6 MTX score @ 12wk100 mg
NCT02886728 · Phase 3 · combination
11.7 vs 11.3 MTX score @ 36wk100 mg
NCT02886728 · Phase 3 · combination
12 vs 11.2 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
DAS28 (CRP) Remission 30.6% (n=147) vs 12.2% (n=148) placebo @ 24wk200 mg
responder rate · % of participants
NCT02873936 · Phase 3
show 35 more results
10.2% (n=147) vs 2.7% (n=148) placebo @ 4wk200 mg
NCT02873936 · Phase 3
22.4% (n=147) vs 8.1% (n=148) placebo @ 12wk200 mg
NCT02873936 · Phase 3
42.4% (n=210) vs 29.1% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
10% (n=210) vs 1% (n=416) MTX @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
19.5% (n=210) vs 4.8% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
29.5% (n=210) vs 17.1% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
43.3% (n=210) vs 34.4% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
46.2% (n=210) vs 31.5% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
34.1% (n=475) vs 9.3% (n=475) placebo @ 12wk200 mg
NCT02889796 · Phase 3
5.1% (n=475) vs 0.6% (n=475) placebo @ 2wk200 mg
NCT02889796 · Phase 3
13.7% (n=475) vs 2.9% (n=475) placebo @ 4wk200 mg
NCT02889796 · Phase 3
48.4% (n=475) vs 16.2% (n=475) placebo @ 24wk200 mg
NCT02889796 · Phase 3
50.3% (n=475) vs 52.1% (n=190) placebo @ 36wk200 mg
NCT02889796 · Phase 3
54.5% (n=475) vs 50.5% (n=190) placebo @ 52wk200 mg
NCT02889796 · Phase 3
26.1% (n=153) vs 12.2% (n=148) placebo @ 24wk100 mg
NCT02873936 · Phase 3
11.8% (n=153) vs 2.7% (n=148) placebo @ 4wk100 mg
NCT02873936 · Phase 3
25.5% (n=153) vs 8.1% (n=148) placebo @ 12wk100 mg
NCT02873936 · Phase 3
23.8% (n=480) vs 9.3% (n=475) placebo @ 12wk100 mg
NCT02889796 · Phase 3
1.7% (n=480) vs 0.6% (n=475) placebo @ 2wk100 mg
NCT02889796 · Phase 3
8.8% (n=480) vs 2.9% (n=475) placebo @ 4wk100 mg
NCT02889796 · Phase 3
35.2% (n=480) vs 16.2% (n=475) placebo @ 24wk100 mg
NCT02889796 · Phase 3
42.9% (n=480) vs 52.1% (n=190) placebo @ 36wk100 mg
NCT02889796 · Phase 3
44.8% (n=480) vs 50.5% (n=190) placebo @ 52wk100 mg
NCT02889796 · Phase 3
54.1% (n=416) vs 29.1% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · combination
7.2% (n=416) vs 1% (n=416) MTX @ 2wk200 mg
NCT02886728 · Phase 3 · combination
16.6% (n=416) vs 4.8% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · combination
39.7% (n=416) vs 17.1% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · combination
52.6% (n=416) vs 34.4% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · combination
53.4% (n=416) vs 31.5% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · combination
42.5% (n=207) vs 29.1% (n=416) MTX @ 24wk100 mg
NCT02886728 · Phase 3 · combination
4.3% (n=207) vs 1% (n=416) MTX @ 2wk100 mg
NCT02886728 · Phase 3 · combination
15% (n=207) vs 4.8% (n=416) MTX @ 4wk100 mg
NCT02886728 · Phase 3 · combination
31.9% (n=207) vs 17.1% (n=416) MTX @ 12wk100 mg
NCT02886728 · Phase 3 · combination
42% (n=207) vs 34.4% (n=416) MTX @ 36wk100 mg
NCT02886728 · Phase 3 · combination
43% (n=207) vs 31.5% (n=416) MTX @ 52wk100 mg
NCT02886728 · Phase 3 · combination
FACIT-Fatigue 9.6 vs 4.5 placebo score @ 12wk200 mg
absolute change · score
NCT02873936 · Phase 3
show 54 more results
6.2 vs 2.2 placebo score @ 4wk200 mg
NCT02873936 · Phase 3
11.6 vs 7 placebo score @ 24wk200 mg
NCT02873936 · Phase 3
10.2 vs 10.1 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
6.8 vs 4.3 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
9.4 vs 8.1 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
10.9 vs 11.1 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
11.5 vs 11.3 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
9.2 vs 6.8 placebo score @ 12wk200 mg
NCT02889796 · Phase 3
6.3 vs 3.8 placebo score @ 4wk200 mg
NCT02889796 · Phase 3
10.5 vs 8.4 placebo score @ 24wk200 mg
NCT02889796 · Phase 3
11 vs 12.8 placebo score @ 36wk200 mg
NCT02889796 · Phase 3
11.9 vs 12.9 placebo score @ 52wk200 mg
NCT02889796 · Phase 3
8.5 vs 1.4 placebo score @ 4wk200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
11.2 vs 3.9 placebo score @ 12wk200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
8.5 vs 4.9 placebo score @ 4wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
11.4 vs 5.6 placebo score @ 12wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
11.6 vs 6 placebo score @ 24wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
8.3 vs 4.5 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
6.4 vs 2.2 placebo score @ 4wk100 mg
NCT02873936 · Phase 3
9.8 vs 7 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
9.1 vs 6.8 placebo score @ 12wk100 mg
NCT02889796 · Phase 3
5.7 vs 3.8 placebo score @ 4wk100 mg
NCT02889796 · Phase 3
10.8 vs 8.4 placebo score @ 24wk100 mg
NCT02889796 · Phase 3
11.7 vs 12.8 placebo score @ 36wk100 mg
NCT02889796 · Phase 3
12.2 vs 12.9 placebo score @ 52wk100 mg
NCT02889796 · Phase 3
7.2 vs 1.4 placebo score @ 4wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
10.2 vs 3.9 placebo score @ 12wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
9.1 vs 4.9 placebo score @ 4wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
9.9 vs 4.9 placebo score @ 4wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
9.5 vs 5.6 placebo score @ 12wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
11.3 vs 5.6 placebo score @ 12wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
11.1 vs 6 placebo score @ 24wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
12.8 vs 6 placebo score @ 24wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
10.6 vs 10.1 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · combination
7 vs 4.3 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · combination
9.8 vs 8.1 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · combination
11.3 vs 11.1 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · combination
11.7 vs 11.3 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
11.4 vs 10.1 MTX score @ 24wk100 mg
NCT02886728 · Phase 3 · combination
6.7 vs 4.3 MTX score @ 4wk100 mg
NCT02886728 · Phase 3 · combination
9.2 vs 8.1 MTX score @ 12wk100 mg
NCT02886728 · Phase 3 · combination
11.9 vs 11.1 MTX score @ 36wk100 mg
NCT02886728 · Phase 3 · combination
11.9 vs 11.3 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
7.2 vs 1.4 placebo score @ 4wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
9.5 vs 3.9 placebo score @ 12wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
4.4 vs 4.9 placebo score @ 4wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
6.6 vs 4.9 placebo score @ 4wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
7.6 vs 5.6 placebo score @ 12wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
8.4 vs 5.6 placebo score @ 12wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
7.9 vs 6 placebo score @ 24wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
9 vs 6 placebo score @ 24wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
4.5 vs 4.9 placebo score @ 4wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
6.9 vs 5.6 placebo score @ 12wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
7.7 vs 6 placebo score @ 24wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
ACR50 22.4% (n=147) vs 7.4% (n=148) placebo @ 4wk200 mg
responder rate · % of participants
NCT02873936 · Phase 3
show 87 more results
42.9% (n=147) vs 14.9% (n=148) placebo @ 12wk200 mg
NCT02873936 · Phase 3
45.6% (n=147) vs 18.9% (n=148) placebo @ 24wk200 mg
NCT02873936 · Phase 3
16.2% (n=210) vs 2.9% (n=416) MTX @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
25.7% (n=210) vs 9.4% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
45.7% (n=210) vs 28.4% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
58.1% (n=210) vs 45.7% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
58.6% (n=210) vs 48.6% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
61.4% (n=210) vs 48.3% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
9.1% (n=475) vs 1.1% (n=475) placebo @ 2wk200 mg
NCT02889796 · Phase 3
22.3% (n=475) vs 5.9% (n=475) placebo @ 4wk200 mg
NCT02889796 · Phase 3
47.2% (n=475) vs 19.8% (n=475) placebo @ 12wk200 mg
NCT02889796 · Phase 3
57.9% (n=475) vs 33.3% (n=475) placebo @ 24wk200 mg
NCT02889796 · Phase 3
63.2% (n=475) vs 67.9% (n=190) placebo @ 36wk200 mg
NCT02889796 · Phase 3
64.2% (n=475) vs 68.4% (n=190) placebo @ 52wk200 mg
NCT02889796 · Phase 3
7.2% (n=69) vs 1.4% (n=72) placebo @ 1wk200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
21.7% (n=69) vs 4.2% (n=72) placebo @ 2wk200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
23.2% (n=69) vs 4.2% (n=72) placebo @ 4wk200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
31.9% (n=69) vs 5.6% (n=72) placebo @ 8wk200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
43.5% (n=69) vs 11.1% (n=72) placebo @ 12wk200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
4.7% (n=86) vs 1.2% (n=86) placebo @ 1wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
10.5% (n=86) vs 5.8% (n=86) placebo @ 2wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
17.4% (n=86) vs 7% (n=86) placebo @ 4wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
33.7% (n=86) vs 12.8% (n=86) placebo @ 8wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
43% (n=86) vs 15.1% (n=86) placebo @ 12wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
50% (n=86) vs 16.3% (n=86) placebo @ 24wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
21.6% (n=153) vs 7.4% (n=148) placebo @ 4wk100 mg
NCT02873936 · Phase 3
32% (n=153) vs 14.9% (n=148) placebo @ 12wk100 mg
NCT02873936 · Phase 3
35.3% (n=153) vs 18.9% (n=148) placebo @ 24wk100 mg
NCT02873936 · Phase 3
5.8% (n=480) vs 1.1% (n=475) placebo @ 2wk100 mg
NCT02889796 · Phase 3
12.9% (n=480) vs 5.9% (n=475) placebo @ 4wk100 mg
NCT02889796 · Phase 3
36.5% (n=480) vs 19.8% (n=475) placebo @ 12wk100 mg
NCT02889796 · Phase 3
52.7% (n=480) vs 33.3% (n=475) placebo @ 24wk100 mg
NCT02889796 · Phase 3
57.7% (n=480) vs 67.9% (n=190) placebo @ 36wk100 mg
NCT02889796 · Phase 3
60.6% (n=480) vs 68.4% (n=190) placebo @ 52wk100 mg
NCT02889796 · Phase 3
10% (n=70) vs 1.4% (n=72) placebo @ 1wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
7.1% (n=70) vs 4.2% (n=72) placebo @ 2wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
18.6% (n=70) vs 4.2% (n=72) placebo @ 4wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
25.7% (n=70) vs 5.6% (n=72) placebo @ 8wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
37.1% (n=70) vs 11.1% (n=72) placebo @ 12wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
4.7% (n=85) vs 1.2% (n=86) placebo @ 1wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
7.1% (n=84) vs 1.2% (n=86) placebo @ 1wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
20% (n=85) vs 5.8% (n=86) placebo @ 2wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
21.4% (n=84) vs 5.8% (n=86) placebo @ 2wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
32.9% (n=85) vs 7% (n=86) placebo @ 4wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
34.5% (n=84) vs 7% (n=86) placebo @ 4wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
35.3% (n=85) vs 12.8% (n=86) placebo @ 8wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
45.2% (n=84) vs 12.8% (n=86) placebo @ 8wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
37.6% (n=85) vs 15.1% (n=86) placebo @ 12wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
54.8% (n=84) vs 15.1% (n=86) placebo @ 12wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
47.1% (n=85) vs 16.3% (n=86) placebo @ 24wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
54.8% (n=84) vs 16.3% (n=86) placebo @ 24wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
13% (n=416) vs 2.9% (n=416) MTX @ 2wk200 mg
NCT02886728 · Phase 3 · combination
29.3% (n=416) vs 9.4% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · combination
53.1% (n=416) vs 28.4% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · combination
61.5% (n=416) vs 45.7% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · combination
60.6% (n=416) vs 48.6% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · combination
62.3% (n=416) vs 48.3% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · combination
9.2% (n=207) vs 2.9% (n=416) MTX @ 2wk100 mg
NCT02886728 · Phase 3 · combination
20.8% (n=207) vs 9.4% (n=416) MTX @ 4wk100 mg
NCT02886728 · Phase 3 · combination
44.4% (n=207) vs 28.4% (n=416) MTX @ 12wk100 mg
NCT02886728 · Phase 3 · combination
57% (n=207) vs 45.7% (n=416) MTX @ 24wk100 mg
NCT02886728 · Phase 3 · combination
55.6% (n=207) vs 48.6% (n=416) MTX @ 36wk100 mg
NCT02886728 · Phase 3 · combination
59.4% (n=207) vs 48.3% (n=416) MTX @ 52wk100 mg
NCT02886728 · Phase 3 · combination
1.4% (n=72) vs 1.4% (n=72) placebo @ 1wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
5.6% (n=72) vs 4.2% (n=72) placebo @ 2wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
15.3% (n=72) vs 4.2% (n=72) placebo @ 4wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
16.7% (n=72) vs 5.6% (n=72) placebo @ 8wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
34.7% (n=72) vs 11.1% (n=72) placebo @ 12wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
2.4% (n=82) vs 1.2% (n=86) placebo @ 1wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
7.1% (n=85) vs 1.2% (n=86) placebo @ 1wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
7.3% (n=82) vs 5.8% (n=86) placebo @ 2wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
11.8% (n=85) vs 5.8% (n=86) placebo @ 2wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
13.4% (n=82) vs 7% (n=86) placebo @ 4wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
18.8% (n=85) vs 7% (n=86) placebo @ 4wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
26.8% (n=82) vs 12.8% (n=86) placebo @ 8wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
34.1% (n=85) vs 12.8% (n=86) placebo @ 8wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
32.9% (n=82) vs 15.1% (n=86) placebo @ 12wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
34.1% (n=85) vs 15.1% (n=86) placebo @ 12wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
35.4% (n=82) vs 16.3% (n=86) placebo @ 24wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
35.3% (n=85) vs 16.3% (n=86) placebo @ 24wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
3.5% (n=86) vs 1.2% (n=86) placebo @ 1wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
7% (n=86) vs 5.8% (n=86) placebo @ 2wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
15.1% (n=86) vs 7% (n=86) placebo @ 4wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
25.6% (n=86) vs 12.8% (n=86) placebo @ 8wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
27.9% (n=86) vs 15.1% (n=86) placebo @ 12wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
34.9% (n=86) vs 16.3% (n=86) placebo @ 24wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
47.6% (n=21) vs 22.7% (n=22) placebo @ 12wk
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
ACR70 6.1% (n=147) vs 2.7% (n=148) placebo @ 4wk200 mg
responder rate · % of participants
NCT02873936 · Phase 3
show 87 more results
21.8% (n=147) vs 6.8% (n=148) placebo @ 12wk200 mg
NCT02873936 · Phase 3
32% (n=147) vs 8.1% (n=148) placebo @ 24wk200 mg
NCT02873936 · Phase 3
4.3% (n=210) vs 0.7% (n=416) MTX @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
11.4% (n=210) vs 3.8% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
29% (n=210) vs 13.2% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
40% (n=210) vs 26% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
39.5% (n=210) vs 32.2% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
45.2% (n=210) vs 29.8% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
2.7% (n=475) vs 0.4% (n=475) placebo @ 2wk200 mg
NCT02889796 · Phase 3
9.1% (n=475) vs 1.5% (n=475) placebo @ 4wk200 mg
NCT02889796 · Phase 3
26.1% (n=475) vs 6.7% (n=475) placebo @ 12wk200 mg
NCT02889796 · Phase 3
36.2% (n=475) vs 14.9% (n=475) placebo @ 24wk200 mg
NCT02889796 · Phase 3
40.2% (n=475) vs 44.7% (n=190) placebo @ 36wk200 mg
NCT02889796 · Phase 3
44.4% (n=475) vs 48.4% (n=190) placebo @ 52wk200 mg
NCT02889796 · Phase 3
1.4% (n=69) vs 0% (n=72) placebo @ 1wk200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
4.3% (n=69) vs 2.8% (n=72) placebo @ 2wk200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
11.6% (n=69) vs 1.4% (n=72) placebo @ 4wk200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
17.4% (n=69) vs 2.8% (n=72) placebo @ 8wk200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
13% (n=69) vs 2.8% (n=72) placebo @ 12wk200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
1.2% (n=86) vs 1.2% (n=86) placebo @ 1wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
5.8% (n=86) vs 1.2% (n=86) placebo @ 2wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
4.7% (n=86) vs 3.5% (n=86) placebo @ 4wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
18.6% (n=86) vs 7% (n=86) placebo @ 8wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
24.4% (n=86) vs 8.1% (n=86) placebo @ 12wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
29.1% (n=86) vs 9.3% (n=86) placebo @ 24wk200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
8.5% (n=153) vs 2.7% (n=148) placebo @ 4wk100 mg
NCT02873936 · Phase 3
14.4% (n=153) vs 6.8% (n=148) placebo @ 12wk100 mg
NCT02873936 · Phase 3
20.3% (n=153) vs 8.1% (n=148) placebo @ 24wk100 mg
NCT02873936 · Phase 3
1.3% (n=480) vs 0.4% (n=475) placebo @ 2wk100 mg
NCT02889796 · Phase 3
3.3% (n=480) vs 1.5% (n=475) placebo @ 4wk100 mg
NCT02889796 · Phase 3
18.5% (n=480) vs 6.7% (n=475) placebo @ 12wk100 mg
NCT02889796 · Phase 3
29.6% (n=480) vs 14.9% (n=475) placebo @ 24wk100 mg
NCT02889796 · Phase 3
35.4% (n=480) vs 44.7% (n=190) placebo @ 36wk100 mg
NCT02889796 · Phase 3
39% (n=480) vs 48.4% (n=190) placebo @ 52wk100 mg
NCT02889796 · Phase 3
1.4% (n=70) vs 0% (n=72) placebo @ 1wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
1.4% (n=70) vs 2.8% (n=72) placebo @ 2wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
5.7% (n=70) vs 1.4% (n=72) placebo @ 4wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
11.4% (n=70) vs 2.8% (n=72) placebo @ 8wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
18.6% (n=70) vs 2.8% (n=72) placebo @ 12wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
0% (n=85) vs 1.2% (n=86) placebo @ 1wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
4.8% (n=84) vs 1.2% (n=86) placebo @ 1wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
7.1% (n=85) vs 1.2% (n=86) placebo @ 2wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
3.6% (n=84) vs 1.2% (n=86) placebo @ 2wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
14.1% (n=85) vs 3.5% (n=86) placebo @ 4wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
10.7% (n=84) vs 3.5% (n=86) placebo @ 4wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
23.5% (n=85) vs 7% (n=86) placebo @ 8wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
27.4% (n=84) vs 7% (n=86) placebo @ 8wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
21.2% (n=85) vs 8.1% (n=86) placebo @ 12wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
31% (n=84) vs 8.1% (n=86) placebo @ 12wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
32.9% (n=85) vs 9.3% (n=86) placebo @ 24wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
39.3% (n=84) vs 9.3% (n=86) placebo @ 24wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
3.1% (n=416) vs 0.7% (n=416) MTX @ 2wk200 mg
NCT02886728 · Phase 3 · combination
13% (n=416) vs 3.8% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · combination
32.9% (n=416) vs 13.2% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · combination
43.8% (n=416) vs 26% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · combination
45.9% (n=416) vs 32.2% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · combination
47.8% (n=416) vs 29.8% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · combination
1.9% (n=207) vs 0.7% (n=416) MTX @ 2wk100 mg
NCT02886728 · Phase 3 · combination
6.3% (n=207) vs 3.8% (n=416) MTX @ 4wk100 mg
NCT02886728 · Phase 3 · combination
27.1% (n=207) vs 13.2% (n=416) MTX @ 12wk100 mg
NCT02886728 · Phase 3 · combination
40.1% (n=207) vs 26% (n=416) MTX @ 24wk100 mg
NCT02886728 · Phase 3 · combination
37.2% (n=207) vs 32.2% (n=416) MTX @ 36wk100 mg
NCT02886728 · Phase 3 · combination
40.1% (n=207) vs 29.8% (n=416) MTX @ 52wk100 mg
NCT02886728 · Phase 3 · combination
0% (n=72) vs 0% (n=72) placebo @ 1wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
1.4% (n=72) vs 2.8% (n=72) placebo @ 2wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
8.3% (n=72) vs 1.4% (n=72) placebo @ 4wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
6.9% (n=72) vs 2.8% (n=72) placebo @ 8wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
8.3% (n=72) vs 2.8% (n=72) placebo @ 12wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
0% (n=82) vs 1.2% (n=86) placebo @ 1wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
2.4% (n=85) vs 1.2% (n=86) placebo @ 1wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
2.4% (n=82) vs 1.2% (n=86) placebo @ 2wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
5.9% (n=85) vs 1.2% (n=86) placebo @ 2wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
7.3% (n=82) vs 3.5% (n=86) placebo @ 4wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
9.4% (n=85) vs 3.5% (n=86) placebo @ 4wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
11% (n=82) vs 7% (n=86) placebo @ 8wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
14.1% (n=85) vs 7% (n=86) placebo @ 8wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
15.9% (n=82) vs 8.1% (n=86) placebo @ 12wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
18.8% (n=85) vs 8.1% (n=86) placebo @ 12wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
22% (n=82) vs 9.3% (n=86) placebo @ 24wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
23.5% (n=85) vs 9.3% (n=86) placebo @ 24wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
1.2% (n=86) vs 1.2% (n=86) placebo @ 1wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
2.3% (n=86) vs 1.2% (n=86) placebo @ 2wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
5.8% (n=86) vs 3.5% (n=86) placebo @ 4wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
9.3% (n=86) vs 7% (n=86) placebo @ 8wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
14% (n=86) vs 8.1% (n=86) placebo @ 12wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
20.9% (n=86) vs 9.3% (n=86) placebo @ 24wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
38.1% (n=21) vs 13.6% (n=22) placebo @ 12wk
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
Tender Joint Count -13 vs -8 placebo count @ 4wk200 mg
absolute change · count
NCT02873936 · Phase 3
show 35 more results
-18 vs -12 placebo count @ 12wk200 mg
NCT02873936 · Phase 3
-22 vs -17 placebo count @ 24wk200 mg
NCT02873936 · Phase 3
-9 vs -5 MTX count @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
-13 vs -8 MTX count @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
-18 vs -15 MTX count @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
-22 vs -19 MTX count @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
-23 vs -21 MTX count @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
-23 vs -21 MTX count @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
-8 vs -5 placebo count @ 2wk200 mg
NCT02889796 · Phase 3
-11 vs -8 placebo count @ 4wk200 mg
NCT02889796 · Phase 3
-17 vs -13 placebo count @ 12wk200 mg
NCT02889796 · Phase 3
-20 vs -17 placebo count @ 24wk200 mg
NCT02889796 · Phase 3
-21 vs -21 placebo count @ 36wk200 mg
NCT02889796 · Phase 3
-21 vs -21 placebo count @ 52wk200 mg
NCT02889796 · Phase 3
-11 vs -8 placebo count @ 4wk100 mg
NCT02873936 · Phase 3
-16 vs -12 placebo count @ 12wk100 mg
NCT02873936 · Phase 3
-19 vs -17 placebo count @ 24wk100 mg
NCT02873936 · Phase 3
-7 vs -5 placebo count @ 2wk100 mg
NCT02889796 · Phase 3
-10 vs -8 placebo count @ 4wk100 mg
NCT02889796 · Phase 3
-15 vs -13 placebo count @ 12wk100 mg
NCT02889796 · Phase 3
-19 vs -17 placebo count @ 24wk100 mg
NCT02889796 · Phase 3
-20 vs -21 placebo count @ 36wk100 mg
NCT02889796 · Phase 3
-21 vs -21 placebo count @ 52wk100 mg
NCT02889796 · Phase 3
-9 vs -5 MTX count @ 2wk200 mg
NCT02886728 · Phase 3 · combination
-13 vs -8 MTX count @ 4wk200 mg
NCT02886728 · Phase 3 · combination
-18 vs -15 MTX count @ 12wk200 mg
NCT02886728 · Phase 3 · combination
-20 vs -19 MTX count @ 24wk200 mg
NCT02886728 · Phase 3 · combination
-21 vs -21 MTX count @ 36wk200 mg
NCT02886728 · Phase 3 · combination
-22 vs -21 MTX count @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-8 vs -5 MTX count @ 2wk100 mg
NCT02886728 · Phase 3 · combination
-12 vs -8 MTX count @ 4wk100 mg
NCT02886728 · Phase 3 · combination
-17 vs -15 MTX count @ 12wk100 mg
NCT02886728 · Phase 3 · combination
-20 vs -19 MTX count @ 24wk100 mg
NCT02886728 · Phase 3 · combination
-21 vs -21 MTX count @ 36wk100 mg
NCT02886728 · Phase 3 · combination
-21 vs -21 MTX count @ 52wk100 mg
NCT02886728 · Phase 3 · combination
Swollen Joint Count -10 vs -7 placebo count @ 4wk200 mg
absolute change · count
NCT02873936 · Phase 3
show 35 more results
-12 vs -8 placebo count @ 12wk200 mg
NCT02873936 · Phase 3
-14 vs -12 placebo count @ 24wk200 mg
NCT02873936 · Phase 3
-7 vs -4 MTX count @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
-9 vs -6 MTX count @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
-13 vs -11 MTX count @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
-15 vs -13 MTX count @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
-15 vs -14 MTX count @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
-16 vs -14 MTX count @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
-6 vs -5 placebo count @ 2wk200 mg
NCT02889796 · Phase 3
-8 vs -6 placebo count @ 4wk200 mg
NCT02889796 · Phase 3
-11 vs -10 placebo count @ 12wk200 mg
NCT02889796 · Phase 3
-13 vs -12 placebo count @ 24wk200 mg
NCT02889796 · Phase 3
-14 vs -14 placebo count @ 36wk200 mg
NCT02889796 · Phase 3
-14 vs -14 placebo count @ 52wk200 mg
NCT02889796 · Phase 3
-7 vs -7 placebo count @ 4wk100 mg
NCT02873936 · Phase 3
-10 vs -8 placebo count @ 12wk100 mg
NCT02873936 · Phase 3
-13 vs -12 placebo count @ 24wk100 mg
NCT02873936 · Phase 3
-5 vs -5 placebo count @ 2wk100 mg
NCT02889796 · Phase 3
-8 vs -6 placebo count @ 4wk100 mg
NCT02889796 · Phase 3
-11 vs -10 placebo count @ 12wk100 mg
NCT02889796 · Phase 3
-13 vs -12 placebo count @ 24wk100 mg
NCT02889796 · Phase 3
-13 vs -14 placebo count @ 36wk100 mg
NCT02889796 · Phase 3
-13 vs -14 placebo count @ 52wk100 mg
NCT02889796 · Phase 3
-7 vs -4 MTX count @ 2wk200 mg
NCT02886728 · Phase 3 · combination
-9 vs -6 MTX count @ 4wk200 mg
NCT02886728 · Phase 3 · combination
-13 vs -11 MTX count @ 12wk200 mg
NCT02886728 · Phase 3 · combination
-14 vs -13 MTX count @ 24wk200 mg
NCT02886728 · Phase 3 · combination
-14 vs -14 MTX count @ 36wk200 mg
NCT02886728 · Phase 3 · combination
-15 vs -14 MTX count @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-6 vs -4 MTX count @ 2wk100 mg
NCT02886728 · Phase 3 · combination
-9 vs -6 MTX count @ 4wk100 mg
NCT02886728 · Phase 3 · combination
-12 vs -11 MTX count @ 12wk100 mg
NCT02886728 · Phase 3 · combination
-14 vs -13 MTX count @ 24wk100 mg
NCT02886728 · Phase 3 · combination
-14 vs -14 MTX count @ 36wk100 mg
NCT02886728 · Phase 3 · combination
-14 vs -14 MTX count @ 52wk100 mg
NCT02886728 · Phase 3 · combination
Patient Global Assessment -21 vs -10 placebo score @ 4wk200 mg
absolute change · score
NCT02873936 · Phase 3
show 35 more results
-31 vs -14 placebo score @ 12wk200 mg
NCT02873936 · Phase 3
-38 vs -24 placebo score @ 24wk200 mg
NCT02873936 · Phase 3
-14 vs -7 MTX score @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
-22 vs -14 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
-32 vs -25 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
-38 vs -34 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
-39 vs -38 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
-43 vs -38 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
-16 vs -8 placebo score @ 2wk200 mg
NCT02889796 · Phase 3
-22 vs -13 placebo score @ 4wk200 mg
NCT02889796 · Phase 3
-33 vs -21 placebo score @ 12wk200 mg
NCT02889796 · Phase 3
-39 vs -31 placebo score @ 24wk200 mg
NCT02889796 · Phase 3
-42 vs -45 placebo score @ 36wk200 mg
NCT02889796 · Phase 3
-44 vs -45 placebo score @ 52wk200 mg
NCT02889796 · Phase 3
-20 vs -10 placebo score @ 4wk100 mg
NCT02873936 · Phase 3
-27 vs -14 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
-34 vs -24 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
-11 vs -8 placebo score @ 2wk100 mg
NCT02889796 · Phase 3
-16 vs -13 placebo score @ 4wk100 mg
NCT02889796 · Phase 3
-28 vs -21 placebo score @ 12wk100 mg
NCT02889796 · Phase 3
-36 vs -31 placebo score @ 24wk100 mg
NCT02889796 · Phase 3
-39 vs -45 placebo score @ 36wk100 mg
NCT02889796 · Phase 3
-41 vs -45 placebo score @ 52wk100 mg
NCT02889796 · Phase 3
-17 vs -7 MTX score @ 2wk200 mg
NCT02886728 · Phase 3 · combination
-26 vs -14 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · combination
-37 vs -25 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · combination
-42 vs -34 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · combination
-43 vs -38 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · combination
-45 vs -38 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-13 vs -7 MTX score @ 2wk100 mg
NCT02886728 · Phase 3 · combination
-20 vs -14 MTX score @ 4wk100 mg
NCT02886728 · Phase 3 · combination
-30 vs -25 MTX score @ 12wk100 mg
NCT02886728 · Phase 3 · combination
-36 vs -34 MTX score @ 24wk100 mg
NCT02886728 · Phase 3 · combination
-39 vs -38 MTX score @ 36wk100 mg
NCT02886728 · Phase 3 · combination
-41 vs -38 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
Physician Global Assessment -32 vs -19 placebo score @ 4wk200 mg
absolute change · score
NCT02873936 · Phase 3
show 35 more results
-45 vs -28 placebo score @ 12wk200 mg
NCT02873936 · Phase 3
-53 vs -41 placebo score @ 24wk200 mg
NCT02873936 · Phase 3
-23 vs -15 MTX score @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
-30 vs -23 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
-42 vs -38 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
-49 vs -46 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
-52 vs -51 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
-55 vs -51 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
-20 vs -13 placebo score @ 2wk200 mg
NCT02889796 · Phase 3
-28 vs -20 placebo score @ 4wk200 mg
NCT02889796 · Phase 3
-41 vs -34 placebo score @ 12wk200 mg
NCT02889796 · Phase 3
-48 vs -42 placebo score @ 24wk200 mg
NCT02889796 · Phase 3
-51 vs -53 placebo score @ 36wk200 mg
NCT02889796 · Phase 3
-53 vs -54 placebo score @ 52wk200 mg
NCT02889796 · Phase 3
-30 vs -19 placebo score @ 4wk100 mg
NCT02873936 · Phase 3
-41 vs -28 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
-45 vs -41 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
-18 vs -13 placebo score @ 2wk100 mg
NCT02889796 · Phase 3
-26 vs -20 placebo score @ 4wk100 mg
NCT02889796 · Phase 3
-39 vs -34 placebo score @ 12wk100 mg
NCT02889796 · Phase 3
-46 vs -42 placebo score @ 24wk100 mg
NCT02889796 · Phase 3
-49 vs -53 placebo score @ 36wk100 mg
NCT02889796 · Phase 3
-50 vs -54 placebo score @ 52wk100 mg
NCT02889796 · Phase 3
-24 vs -15 MTX score @ 2wk200 mg
NCT02886728 · Phase 3 · combination
-34 vs -23 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · combination
-47 vs -38 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · combination
-51 vs -46 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · combination
-53 vs -51 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · combination
-56 vs -51 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-21 vs -15 MTX score @ 2wk100 mg
NCT02886728 · Phase 3 · combination
-32 vs -23 MTX score @ 4wk100 mg
NCT02886728 · Phase 3 · combination
-43 vs -38 MTX score @ 12wk100 mg
NCT02886728 · Phase 3 · combination
-51 vs -46 MTX score @ 24wk100 mg
NCT02886728 · Phase 3 · combination
-51 vs -51 MTX score @ 36wk100 mg
NCT02886728 · Phase 3 · combination
-54 vs -51 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination

+ 266 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: filgotinib's landscape · Zemprocitinib's landscape